Emerson today announced that it has completed the purchase of the Valves & Controls business from Pentair for $3.15 billion.
“This acquisition enables us to continue to grow our global footprint in automation and expand our leadership position in key served markets such as chemical, power, refining, mining and oil and gas,” said Chairman and Chief Executive Officer David N. Farr. “By adding these highly respected products and aftermarket services to our portfolio, Emerson is better positioned to serve the needs of our global customers.”
Headquartered in Schaffhausen, Switzerland, the Valves & Controls business is a leading provider of valve solutions and services with nearly 7,500 employees around the world. The business will be integrated into Emerson’s Automation Solutions platform.
Mike Train, Automation Solutions executive president, said, “Pentair’s Valves & Controls business fits extremely well with Emerson’s existing portfolio of Fisher control valves and regulators and Bettis actuators. The addition of market leading product brands such as Anderson Greenwood, Vanessa and Keystone creates the most comprehensive global valve business. Emerson’s final control portfolio now includes control valves, pressure relief, butterfly, gate, globe, ball and check valves, and an extensive global network of more than 200 service centers. The combination of these two leading businesses will allow us to better support and help customers select the right product and maintain it for the life of the asset.”
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan